Trial Profile

A phase I/II study of NED-170 for Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NED-170 (Primary)
Indications Breast cancer; Cholangiocarcinoma; Triple negative breast cancer
Focus Therapeutic Use

17 Oct 2019 According to a NED Biosystems media release, the company plans to initiate the study in 2020
29 Apr 2019 According to a NED Biosystems media release, the company is finalizing the protocol for a phase I/IIA clinical trial to investigate the safety and efficacy of NED-170 in 10 patients with treatment-refractory triple-negative breast cancer and 10 with refractory cholangiocarcinoma. The company expects to begin enrollment in the second half of 2019.
12 Feb 2019 According to a NED Biosystems media release, this study is expected to initiate by 1H 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com